2024
Restarting Antithrombotic Therapies After Endoscopic Sinus Surgery: A Systematic Review
Boyi T, Richmond R, Kayastha D, Manes R, Rimmer R. Restarting Antithrombotic Therapies After Endoscopic Sinus Surgery: A Systematic Review. Annals Of Otology Rhinology & Laryngology 2024, 133: 633-638. PMID: 38557289, DOI: 10.1177/00034894241245840.Peer-Reviewed Original ResearchEndoscopic sinus surgeryAntithrombotic therapySinus surgerySystematic reviewResumption of antithrombotic therapyRisk of perioperative hemorrhageFull-text reviewPreferred Reporting ItemsCase-control studyWeb of ScienceCINAHL databasesReporting ItemsIndependent reviewersUnique articlesPerioperative hemorrhageTherapy resumptionCohort studyAntiplatelet therapyInclusion criteriaPatient morbidityAntiplatelet agentsPrimary outcomeTherapySurgeryAntiplatelet
2022
Antiplatelet regimens following carotid artery revascularization
Lee M, Ahmed ZV, Huang J, Brice A, Arham A, Castro-Dominguez Y, Aboian E, Nagpal S, Smolderen KG, Mena-Hurtado C. Antiplatelet regimens following carotid artery revascularization. American Heart Journal 2022, 253: 48-52. PMID: 35863439, DOI: 10.1016/j.ahj.2022.07.004.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapySingle antiplatelet therapyCarotid artery stentingCarotid endarterectomyAntiplatelet therapyReal-world clinical practiceCarotid artery revascularizationLow adherence ratesArtery revascularizationArtery stentingAdherence ratesClinical practicePatientsTherapyEngland dataHigh percentageRevascularizationAntiplateletEndarterectomyStentingManagement of Patients on Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Peri-Endoscopic Period: A Clinical Practice Guideline Dissemination Tool
Barkun AN, Douketis J, Noseworthy PA, Laine L, Telford JJ, Abraham NS. Management of Patients on Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Peri-Endoscopic Period: A Clinical Practice Guideline Dissemination Tool. The American Journal Of Gastroenterology 2022, 117: 513-519. PMID: 35354773, DOI: 10.14309/ajg.0000000000001688.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2021
GUIDELINE CONCORDANT ANTIPLATELET REGIMENS IN PATIENTS WHO UNDERWENT CAROTID ARTERY REVASCULARIZATION: INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE REGISTRY
Ahmed Z, Lee M, Huang J, Brice A, Arham A, Dominguez Y, Aboian E, Nagpal S, Smolderen K, Hurtado C. GUIDELINE CONCORDANT ANTIPLATELET REGIMENS IN PATIENTS WHO UNDERWENT CAROTID ARTERY REVASCULARIZATION: INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE REGISTRY. Journal Of The American College Of Cardiology 2021, 77: 1078. DOI: 10.1016/s0735-1097(21)02437-2.Peer-Reviewed Original ResearchDuration of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement: Systematic Review and Network Meta‐Analysis
Kuno T, Yokoyama Y, Briasoulis A, Mori M, Iwagami M, Ando T, Takagi H, Bangalore S. Duration of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement: Systematic Review and Network Meta‐Analysis. Journal Of The American Heart Association 2021, 10: e019490. PMID: 33870703, PMCID: PMC8200731, DOI: 10.1161/jaha.120.019490.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAntiplatelet therapy groupLife-threatening bleedingAortic valve replacementAntiplatelet therapyDuration of DAPTAll-Cause MortalityDAPT groupNetwork Meta-AnalysisValve replacementRisk ratioTherapy groupPropensity-score matched studyDuration of antiplatelet therapySingle antiplatelet therapyRate of strokeRandomized Controlled TrialsOral anticoagulantsPooled analysisDAPT useClinical studiesCochrane DatabaseTherapyAntiplateletObservational study
2019
ANTIPLATELET THERAPY PRESCRIPTION PATTERNS AND ASSOCIATIONS WITH CLINICAL OUTCOMES IN MEDICARE BENEFICIARIES WITH ATRIAL FIBRILLATION PRESCRIBED NO ORAL ANTICOAGULATION AFTER ACUTE ISCHEMIC STROKE
Chang K, Xian Y, Zhao X, Matsouaka R, Schwamm L, Fonarow G, Bhatt D, Shah S, Lytle B, Smith E, Hsu J. ANTIPLATELET THERAPY PRESCRIPTION PATTERNS AND ASSOCIATIONS WITH CLINICAL OUTCOMES IN MEDICARE BENEFICIARIES WITH ATRIAL FIBRILLATION PRESCRIBED NO ORAL ANTICOAGULATION AFTER ACUTE ISCHEMIC STROKE. Journal Of The American College Of Cardiology 2019, 73: 364. DOI: 10.1016/s0735-1097(19)30972-6.Peer-Reviewed Original Research
2018
CAUSES AND IMPACT OF PREMATURE INTERRUPTION OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACTIVE CANCER
Lombardo M, Kampaktsis P, Feher A, Mantha S, Baber U, Steingart R, Gupta D. CAUSES AND IMPACT OF PREMATURE INTERRUPTION OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACTIVE CANCER. Journal Of The American College Of Cardiology 2018, 71: a116. DOI: 10.1016/s0735-1097(18)30657-0.Peer-Reviewed Original Research
2017
Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants?
Gettel C, Goldberg EM. Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? Annals Of Emergency Medicine 2017, 72: 547-549. PMID: 29174831, PMCID: PMC7061881, DOI: 10.1016/j.annemergmed.2017.10.011.Peer-Reviewed Original Research
1997
Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease
Schussheim A, Fuster V. Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. Progress In Cardiovascular Diseases 1997, 40: 205-238. PMID: 9406677, DOI: 10.1016/s0033-0620(97)80035-7.Peer-Reviewed Original ResearchConceptsThrombus formationAntithrombotic agentsAnticoagulant agentsCardiac diseaseUse of antiplateletUnderstanding of pathogenesisRational approachAntithrombotic therapyAntithrombotic approachAntiplatelet agentsConcomitant useDisease entityRelative riskHigh riskLower riskThrombosisHemostatic processAntiplateletAntithromboticsRiskDiseaseMedium riskAgentsThromboembolismAnticoagulants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply